Literature DB >> 27824253

A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability.

Ethel D Weld1,2, Hiwot Hiruy1,3, Kate Morrow Guthrie4,5, Joseph L Fava4, Sara E Vargas4,5, Karen Buckheit6, Robert Buckheit6, Hans Spiegel7, Jennifer Breakey1, Edward J Fuchs1, Craig W Hendrix1,2.   

Abstract

For persons at risk of HIV infection who practice receptive anal intercourse (RAI), topical rectal microbicides represent a promising option for coitally dependent protection. The study compared colorectal distribution and user sensory experiences of two different volumes of rectal gel for suitability as rectal microbicide. Eight HIV-negative men with a history of recent RAI were enrolled into a two-period, sequence-randomized dosing study comparing 3.5 and 10 ml of radiolabeled (1 mCi 99mTc-DTPA) universal placebo, hydroxyethyl cellulose gel. Each participant received two doses in the research unit, one of each volume, separated by a washout period of at least 2 weeks. Each research unit dose was followed by a self-administered take-home dose in the context of preparing for RAI. Safety and gastrointestinal distribution were assessed after the research unit doses, safety, perceptibility, and acceptability, were assessed after take-home doses. There were no adverse effects of Grade 2 or higher and all resolved spontaneously. Both volumes were well tolerated and received high acceptability scores. Perceptibility scores showed meaningful effect size differences ranging from Cohen's d = 0.5 to d = 1.2. The 3.5 and 10 ml gel volumes distributed similarly (p > .2) within the rectosigmoid, ranging from 0.69 to 18.84 cm and 1.21 to 19.01 cm from the anorectal junction, respectively. Both volumes covered the typical gastrointestinal distribution of ejaculate following simulated intercourse based on other studies. Either of these gel volumes could reasonably be pursued for the next phase of development of rectal microbicides.

Entities:  

Keywords:  acceptability; gastrointestinal distribution; human immunodeficiency virus; microbicide; pharmacokinetics; pre-exposure prophylaxis

Mesh:

Substances:

Year:  2016        PMID: 27824253      PMCID: PMC5439405          DOI: 10.1089/AID.2016.0167

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  34 in total

1.  Distribution of cell-free and cell-associated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men.

Authors:  Nicolette A Louissaint; Sridhar Nimmagadda; Edward J Fuchs; Rahul P Bakshi; Ying-Jun Cao; Linda A Lee; Jeff Goldsmith; Brian S Caffo; Yong Du; Karen E King; Frederick A Menendez; Michael S Torbenson; Craig W Hendrix
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse.

Authors:  Nicolette A Louissaint; Edward J Fuchs; Rahul P Bakshi; Sridhar Nimmagadda; Yong Du; Katarzyna J Macura; Karen E King; Richard Wahl; Arthur J Goldsmith; Brian Caffo; Ying Jun Cao; Jean Anderson; Craig W Hendrix
Journal:  J Infect Dis       Date:  2012-01-25       Impact factor: 5.226

4.  Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates.

Authors:  C W Hendrix; E J Fuchs; K J Macura; L A Lee; T L Parsons; R P Bakshi; W A Khan; A Guidos; J P Leal; R Wahl
Journal:  Clin Pharmacol Ther       Date:  2007-05-16       Impact factor: 6.875

5.  Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties.

Authors:  Kathleen M Morrow; Joseph L Fava; Rochelle K Rosen; Sara Vargas; Julia G Shaw; E Milu Kojic; Patrick F Kiser; David R Friend; David F Katz
Journal:  AIDS Res Hum Retroviruses       Date:  2013-12-09       Impact factor: 2.205

6.  Distribution and morphological characterization of viscerofugal projections from the large intestine to the inferior mesenteric and pelvic ganglia of the male rat.

Authors:  G B Luckensmeyer; J R Keast
Journal:  Neuroscience       Date:  1995-06       Impact factor: 3.590

7.  Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.

Authors:  James Y Dai; Craig W Hendrix; Barbra A Richardson; Cliff Kelly; Mark Marzinke; Z Mike Chirenje; Jeanne M Marrazzo; Elizabeth R Brown
Journal:  J Infect Dis       Date:  2015-06-29       Impact factor: 5.226

8.  Rectal microbicide acceptability: results of a volume escalation trial.

Authors:  Alex Carballo-Diéguez; Theresa Exner; Curtis Dolezal; Robert Pickard; Peter Lin; Kenneth H Mayer
Journal:  Sex Transm Dis       Date:  2007-04       Impact factor: 2.830

9.  Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.

Authors:  Kate Morrow Guthrie; Shira Dunsiger; Sara E Vargas; Joseph L Fava; Julia G Shaw; Rochelle K Rosen; Patrick F Kiser; E Milu Kojic; David R Friend; David F Katz
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-29       Impact factor: 2.205

10.  A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).

Authors:  Ian Mcgowan; Ross D Cranston; Kathryn Duffill; Aaron Siegel; Jarret C Engstrom; Alexyi Nikiforov; Cindy Jacobson; Khaja K Rehman; Julie Elliott; Elena Khanukhova; Kaleab Abebe; Christine Mauck; Hans M L Spiegel; Charlene S Dezzutti; Lisa C Rohan; Mark A Marzinke; Hiwot Hiruy; Craig W Hendrix; Nicola Richardson-Harman; Peter A Anton
Journal:  PLoS One       Date:  2015-05-05       Impact factor: 3.240

View more
  7 in total

Review 1.  Designing and developing suppository formulations for anti-HIV drug delivery.

Authors:  Anthony S Ham; Robert W Buckheit
Journal:  Ther Deliv       Date:  2017-08

2.  User input in iterative design for prevention product development: leveraging interdisciplinary methods to optimize effectiveness.

Authors:  Kate M Guthrie; Rochelle K Rosen; Sara E Vargas; Melissa Guillen; Arielle L Steger; Melissa L Getz; Kelley A Smith; Jaime J Ramirez; Erna M Kojic
Journal:  Drug Deliv Transl Res       Date:  2017-10       Impact factor: 4.617

Review 3.  On-demand microbicide products: design matters.

Authors:  Sravan Kumar Patel; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

4.  Lubricant Provides Poor Rectal Mucosal HIV Coverage.

Authors:  Eugenie C Shieh; Ethel D Weld; Edward J Fuchs; Hiwot Hiruy; Karen W Buckheit; Robert W Buckheit; Jennifer Breakey; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2017-07-24       Impact factor: 2.205

5.  Designing Dual Compartment HIV Prevention Products: Women's Sensory Perceptions and Experiences of Suppositories for Rectal and Vaginal Use.

Authors:  Kate M Guthrie; Rochelle K Rosen; Melissa Guillen; Jaime J Ramirez; Sara E Vargas; Joseph L Fava; Anthony S Ham; David F Katz; Susan Cu-Uvin; Sheila Tumilty; Kelley A Smith; Karen W Buckheit; Robert W Buckheit
Journal:  AIDS Res Hum Retroviruses       Date:  2021-10-18       Impact factor: 1.723

6.  Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026).

Authors:  José A Bauermeister; Ryan C Tingler; Clara Dominguez; Eileen F Dunne; Craig Hoesley; Ken Ho; Sherri Johnson; Jonathan Lucas; Nicole Macagna; Elizabeth Brown; Holly Gundacker; Melissa Peda; Cindy E Jacobson; Lindsay Kramzer; Devika Singh; Charlene S Dezzutti; Ratiya Pamela Kunjara Na Ayudhya; Mark A Marzinke; Jeanna Piper; Bríd Devlin; Jeremy Nuttall; Ian McGowan; Craig W Hendrix; Ross D Cranston
Journal:  AIDS Behav       Date:  2021-10-17

7.  Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.

Authors:  Kathleen Listiak Vincent; John A Moss; Mark A Marzinke; Craig W Hendrix; Peter A Anton; Manjula Gunawardana; Lauren N Dawson; Trevelyn J Olive; Richard B Pyles; Marc M Baum
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.